Anna Rudvik

428 total citations
10 papers, 311 citations indexed

About

Anna Rudvik is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Anna Rudvik has authored 10 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Surgery, 3 papers in Cardiology and Cardiovascular Medicine and 2 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Anna Rudvik's work include Lipoproteins and Cardiovascular Health (3 papers), Heart Failure Treatment and Management (2 papers) and Diabetic Foot Ulcer Assessment and Management (1 paper). Anna Rudvik is often cited by papers focused on Lipoproteins and Cardiovascular Health (3 papers), Heart Failure Treatment and Management (2 papers) and Diabetic Foot Ulcer Assessment and Management (1 paper). Anna Rudvik collaborates with scholars based in Sweden, United States and Finland. Anna Rudvik's co-authors include Regina Fritsche‐Danielson, Li‐Ming Gan, Kenneth R. Chien, Anna Collén, John L. Joyal, Cecilia Arfvidsson, Ligia Chialda, Rainard Fuhr, Michael Kjær and Thomas Koernicke and has published in prestigious journals such as Circulation, Nature Communications and Journal of the American College of Cardiology.

In The Last Decade

Anna Rudvik

10 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Rudvik Sweden 7 190 55 53 45 43 10 311
Magnus Althage Sweden 11 204 1.1× 28 0.5× 69 1.3× 24 0.5× 56 1.3× 23 371
Adrien Lupieri United States 9 108 0.6× 54 1.0× 24 0.5× 23 0.5× 59 1.4× 16 278
Ligia Chialda Sweden 6 171 0.9× 23 0.4× 31 0.6× 25 0.6× 35 0.8× 7 329
Shinan Ma China 9 131 0.7× 41 0.7× 21 0.4× 21 0.5× 18 0.4× 27 262
Yifei Yu China 9 135 0.7× 29 0.5× 24 0.5× 47 1.0× 11 0.3× 23 288
Ju-Eun Hong South Korea 11 217 1.1× 16 0.3× 42 0.8× 12 0.3× 24 0.6× 28 352
Francisco M. Cruz Spain 10 157 0.8× 159 2.9× 69 1.3× 12 0.3× 23 0.5× 16 372
Jeremy Kah Sheng Pang Singapore 10 223 1.2× 36 0.7× 54 1.0× 5 0.1× 30 0.7× 17 309
Supannikar Tawinwung Thailand 9 101 0.5× 43 0.8× 10 0.2× 23 0.5× 44 1.0× 25 289

Countries citing papers authored by Anna Rudvik

Since Specialization
Citations

This map shows the geographic impact of Anna Rudvik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Rudvik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Rudvik more than expected).

Fields of papers citing papers by Anna Rudvik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Rudvik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Rudvik. The network helps show where Anna Rudvik may publish in the future.

Co-authorship network of co-authors of Anna Rudvik

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Rudvik. A scholar is included among the top collaborators of Anna Rudvik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Rudvik. Anna Rudvik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
2.
Koren, Michael J., Alexis Hofherr, Jennifer Schumi, et al.. (2022). ETESIAN: A PHASE 2B STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF AZD8233, A PCSK9-TARGETED ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH DYSLIPIDEMIA. Journal of the American College of Cardiology. 79(9). 1475–1475. 14 indexed citations
3.
Prescott, Eva, Oskar Angerås, David Erlinge, et al.. (2022). Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study. International Journal of Cardiology. 365. 34–40. 8 indexed citations
4.
Anttila, Vesa, Antti Saraste, Juhani Knuuti, et al.. (2022). Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Molecular Therapy. 31(3). 866–874. 54 indexed citations
5.
Squire, Iain, Anders Gabrielsen, Peter J. Greasley, et al.. (2022). Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial. Clinical and Translational Science. 15(10). 2493–2504. 9 indexed citations
6.
7.
Hofherr, Alexis, Jennifer Schumi, Dinko Rekić, et al.. (2022). ETESIAN: A phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia. Atherosclerosis. 355. 28–28. 6 indexed citations
8.
Prescott, Eva, Oskar Angerås, David Erlinge, et al.. (2021). EFFICACY, SAFETY AND TOLERABILITY OF THE 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR AZD5718 IN PATIENTS WITH RECENT MYOCARDIAL INFARCTION: A PHASE 2A STUDY (FLAVOUR). Journal of the American College of Cardiology. 77(18). 136–136. 1 indexed citations
9.
Gan, Li‐Ming, Maria Lagerström‐Fermér, Leif Carlsson, et al.. (2019). Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nature Communications. 10(1). 871–871. 152 indexed citations
10.
Rudvik, Anna, et al.. (2018). Evaluation of surrogate measures of insulin sensitivity - correlation with gold standard is not enough. BMC Medical Research Methodology. 18(1). 64–64. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Magnus Althage Breakdown of academic impact, for papers by Adrien Lupieri Breakdown of academic impact, for papers by Ligia Chialda Breakdown of academic impact, for papers by Shinan Ma Breakdown of academic impact, for papers by Yifei Yu Breakdown of academic impact, for papers by Ju-Eun Hong Breakdown of academic impact, for papers by Francisco M. Cruz Breakdown of academic impact, for papers by Jeremy Kah Sheng Pang Breakdown of academic impact, for papers by Supannikar Tawinwung
Rankless by CCL
2026